100% focused on cancer risk assessment.

Our team has lived and breathed cancer risk assessment for more than 15 years. We’re on a mission of prevention. Join us.
Contact Us
Our mission is to help providers identify patients who have a high risk of cancer and get them on the right clinical pathway earlier. We envision a world in which providers are equipped to recommend the best options for cancer prevention, based on a comprehensive picture of their patients’ risk. And, we are leading the way in creating an industry-wide mindset that puts a priority on risk assessment.

Our History

CRA Health was founded out of research teams at Massachusetts General Hospital, led by Dr. Kevin Hughes, and the University of Massachusetts, led by Brian Drohan, PhD. The research that laid the foundation for CRA Health began in 2004 and the company began commercial operations in 2006. Since then, we have emerged as a leader in cancer risk assessment, with our innovative platform for screening, tracking, and managing high-risk patients. Today, our platform is used by more than 75 teaching hospitals, genetic clinics, and breast imaging centers across the country.

Our Core Goals

Identify high-risk patients.
Explore all risk factors.
Measure a patient’s true risk.
Interpret the risk score.
Communicate the patient’s risk.
Guide the patient’s journey.

Our Valued Traits

Management Team

Brian is an experienced enterprise architect, technical manager, and consultant. He began working on the foundation of CRA Health with Dr. Kevin Hughes at Massachusetts General Hospital in 2004. Since inception, Brian has been integrally involved and responsible for the company’s product development and technology solution. Today, Brian works in close collaboration with healthcare providers, technology professionals, and leadership to ensure CRA Health’s solutions operate efficiently and effectively within organizations, ultimately with the goal of improving patient care and outcomes. Brian earned his PhD in Biomedical Engineering from the University of Massachusetts.

Hai joined CRA Health in June 2017 as the Chief Technology Officer, responsible for defining the technology strategies and managing the technical implementation and operations of CRA Health’s products and services. Hai has more than 20 years of in-depth experience in healthcare information technology and product development for medical imaging, radiology systems, and clinical workflow automation, and has played an important role building advanced system integration software solutions in the healthcare industry. Prior to joining CRA Health, Hai served as Vice President of Engineering at healthcare technology companies lifeIMAGE and AMICAS. Hai has earned his MS in Computer Science from Boston University.

Gregg joined CRA Health in 2015, bringing more than 20 years of healthcare sales experience. As vice president of business development, Gregg is responsible for working with healthcare organizations interested in implementing CRA Health’s innovative cancer risk assessment platform. Gregg is adept at understanding the needs within a facility and ensuring that CRA’s solution is optimized for each client. Throughout his career, Gregg has played a pivotal role in helping healthcare and medical technology companies cultivate and expand their client relationships. He has worked side-by-side with breast surgeons, breast imaging radiologists and radiation oncologists and is deeply embedded within the cancer and oncology healthcare industry. Previously, Gregg was the regional manager for an intraoperative radiotherapy (IORT) device company, where he worked with breast surgeons to bring a groundbreaking new treatment modality to breast cancer patients. Gregg has a BA in organizational communication from Ohio State University.

Are you interested in joining our team?

Send us an email

Medical Advisors

Kevin S. Hughes, MD, FACS, is a co-founder and chief medical advisor to CRA Health LLC. Dr. Hughes is the Massachusetts General Hospital’s Surgical Director of the Breast Screening Program, and Co-Director of the Avon Comprehensive Breast Evaluation Center, and serves as the Medical Director of the Bermuda Cancer Genetics and Risk Assessment Clinic. He is an Associate Professor of Surgery at Harvard Medical School. Dr. Hughes is actively involved in the establishment of standards and in research regarding the genetics, screening, diagnosis, and treatment of breast cancer. He is the author of numerous papers and book chapters on the subjects of breast cancer, screening, diagnosis and treatment, and risk assessment.

David Euhus, MD, is a Professor of Surgery and Chief of Breast Surgery at the Johns Hopkins University School of Medicine in Baltimore, MD. He is the author of the popular cancer genetics software program, CancerGene, which has over 6000 users in more than 75 countries. He was on the faculty of the University of Texas Southwestern Medical Center at Dallas as an Assistant Professor of Surgery from 1996 to 2013. During his 17 years in Dallas he maintained a translational research laboratory focused on biological markers of breast cancer risk and developed one the nation’s largest Clinical Cancer Genetics programs. He completed his General and Oncologic Surgery training at UCLA in 1991 after which he served as a Surgical Oncologist in the US. Army.

Daniel B. Kopans, MD, FACR, is a Professor of Radiology at Harvard Medical School and founder of the Breast Imaging Division at the Massachusetts General Hospital. Dr. Kopans was among the first to recognize the value of Ultrasound, CT, and MRI in breast evaluation and developed the first “Breast Imaging” Division in the U.S. He pioneered innovations in early breast cancer detection, including tomosynthesis, a procedure that increases the accuracy of mammograms without significantly increasing radiation exposure, and the Kopans Wire, a tool that helps clinicians detect small breast tumors.

Giovanni Parmigiani, PhD, is Professor of Biostatistics at Harvard School of Public Health and chair of the Department of Biostatistics and Computational Biology at Dana-Farber Cancer Institute. He is an Associate Director for Population Sciences at the Dana-Farber/Harvard Cancer Center. His research interests include models and software for predicting who is at risk of carrying genetic variants that confer susceptibility to cancer. He is the inventor of BayesMendel, a risk prediction software for Mendelian diseases, and one of the primary developers of BRCAPRO, a model and software for genetic counseling of families at high risk of breast and ovarian cancer.

Learn more about how to enhance your risk assessment program

Contact Us